Innovent Biologics Initiates Phase 3 Trial for Gout Drug IBI128 to Improve Patient Outcomes Innovent Biologics has commenced a Phase 3 study for IBI128, a novel gout treatment, aiming to provide enhanced care for gout patients in China.

Innovent Biologics Initiates Phase 3 Trial for Gout Drug IBI128 to Improve Patient Outcomes #China #Suzhou #Gout_Treatment #Innovent #IBI128